Canagliflozin
4 NDCs across 1 manufacturer|0 Generic,4 Brand
Canagliflozin is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Mar 29, 2013, and the first generic was approved Apr 14, 2026. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $272 million on Canagliflozin across 256,000 claims for 56,000 beneficiaries.
Canagliflozin is available as 4 NDCs from 1 manufacturer (0 generic, 4 brand), with NADAC prices from $19.12 to $19.13 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
4
0G / 4B
Manufacturers
1
competing in market
Price Spread
$19.12 – $19.13
per EA
7d Activity
avg +0.1% WoW · of 4 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Janssen Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Sodium-Glucose Cotransporter 2 Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing CANAGLIFLOZIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
INVOKANA 100 MG TABLET | $19.1269 per EA | +0.09% |
INVOKANA 100 MG TABLET | $19.1269 per EA | +0.09% |
INVOKANA 300 MG TABLET | $19.1248 per EA | +0.03% |
INVOKANA 300 MG TABLET | $19.1248 per EA | +0.03% |
Frequently Asked Questions
What is Canagliflozin used to treat?
Canagliflozin is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
When did Canagliflozin become available as a generic?
FDA approved the first generic Canagliflozin (ANDA) on Apr 14, 2026. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Canagliflozin?
In 2024, Medicare Part D spent $272 million on Canagliflozin across 256,000 claims for 56,000 beneficiaries.
How many Canagliflozin products are on the market?
The Canagliflozin drug market contains 4 NDCs from 1 manufacturer — 0 generic and 4 brand products.
What is the price range for Canagliflozin?
NADAC reference prices for Canagliflozin range from $19.1248 to $19.1269 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Canagliflozin?
1 manufacturer lists Canagliflozin in NADAC. Ranked by number of NDCs, the largest are Janssen Pharmaceuticals Inc. (4).
How has the price of Canagliflozin changed recently?
Over the past 7 days, 4 Canagliflozin NDCs rose and 0 fell, with a market-wide average change of +0.1%.